Name | Brexpiprazole dihydrochloride |
---|
Description | Brexpiprazole (OPC-34712) hydrochloride, an atypical orally active antipsychotic drug, is a partial agonist of human 5-HT1A and dopamine D2L receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole hydrochloride is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM. Brexpiprazole hydrochloride also shows potent antagonist activity at human noradrenergic α1B (Ki=0.17 nM) and α2C receptors (Ki=0.59 nM)[1][2]. |
---|---|
Related Catalog | |
Target |
5-HT1A Receptor:0.12 nM (Ki) 5-HT2A Receptor:0.47 nM (Ki) D2L Receptor:0.3 nM (Ki) human noradrenergic α1B:0.17 nM (Ki) human noradrenergic α2C:0.59 nM (Ki) |
In Vitro | Brexpiprazole (0-1.0 μM, 4 days) potentiates NGF-induced neurite outgrowth in a dose-dependent manner in PC12 cells[1]. |
In Vivo | Brexpiprazole (0-0.1 mg/kg; p.o.; once) improves social recognition deficits in mice[2]. Animal Model: Male C57BL/6NCrSlc mice, Dizocilpine (0.1 mg/kg) (HY-15084B) induced social recognition deficits[2] Dosage: 0.01, 0.03 and 0.1 mg/kg Administration: Oral administration, once Result: Significantly ameliorated Dizocilpine-induced social recognition deficits, without sedation or a reduction of exploratory behavior. |
References |
No Any Chemical & Physical Properties |